Stocks · News reference

8-K filing — Dyne Therapeutics, Inc. (DYN)

Jul 29, 2026, 8:35 PMSEC EDGAR

Filed: 2026-07-29 AccNo: 0001193125-26-323940 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DYN

Source: edgar
Observed: Jul 29, 2026, 8:35 PM
Checked: Jul 29, 2026, 8:35 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 3, 2026, 11:33 AMBenzinga Newsdesk
Dyne Therapeutics To Present Preclinical Data On Four Candidates For Exon 53, 45, 44, And 55 Skipping In DMD At NMSG Meeting September 25; All Advancing Into IND-Enabling Studies
DYN
BenzingaJul 31, 2026, 5:31 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
DYN
BenzingaJul 30, 2026, 5:43 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
DYN
BenzingaJul 29, 2026, 9:33 PMBenzinga Newsdesk
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
DYN

8-K filing — Dyne Therapeutics, Inc. (DYN)

Connected Markets

Related Headlines

Dyne Therapeutics To Present Preclinical Data On Four Candidates For Exon 53, 45, 44, And 55 Skipping In DMD At NMSG Meeting September 25; All Advancing Into IND-Enabling Studies

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate